Read Gene

Read Gene Fixed Asset Turnover

The Fixed Asset Turnover of Read Gene (RDG.WA) as of Nov 6, 2026 is 0.59. In the previous year, Fixed Asset Turnover was 0.56 — a change of 3.98% (higher).

Fixed Asset Turnover

0.59

YoY

3.98%

Last updated:

Fixed Asset Turnover of Read Gene is 2020 0.59 . Fixed Asset Turnover of Read Gene was 2019 0.56 . It decreases by 3.98% higher compared to the previous year.

The Read Gene Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2016
0.66 PLN
Jan 1, 2017
0.33 PLN
Jan 1, 2018
0.64 PLN
Jan 1, 2019
0.56 PLN
Jan 1, 2020
0.59 PLN
The Read Gene Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
0.59+3.98%
0.56-12.13%
0.64+95.22%
0.33-50.28%
0.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Fixed Asset Turnover of Read Gene is 0.59 in 2020.

Fixed Asset Turnover of Read Gene changed from 0.56 to 0.59, representing a 3.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Read Gene since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Read Gene

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Read Gene